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Concurrent TNFRSF1A R92Q and pyrin
E230K mutations in a child with multiple
sclerosis
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Abstract
We report a 16-year-old female patient with a severe course of multiple sclerosis and concomitant symptoms suggestive
of a hereditary autoinflammatory disease. Genetic analyses revealed that she inherited a TNFRSF1A R92Q mutation
from her mother and a pyrin E230K mutation from her father. To our knowledge, this is the first report of a patient with
severe childhood multiple sclerosis and mutations in two genes which predispose to hereditary autoinflammatory
disorders. We speculate that these mutations contribute to early multiple sclerosis manifestation and enhance the
inflammatory damage inflicted by the autoimmune response.
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Background
Tumor necrosis factor receptor 1-associated periodic
syndrome (TRAPS) and Familial Mediterranean
Fever (FMF) belong to the group of hereditary auto-
inflammatory syndromes which are characterized by
recurrent episodes of inflammation and are variably
associated with fever, abdominal and thoracic pain,
arthralgia, myalgia, rashes, and headache.
A few cases of central nervous system (CNS)
involvement have been reported in association with
TRAPS1–2 and FMF,3 and Jewish multiple sclerosis
(MS) patients carrying one Mediterranean fever gene
(MEFV) mutation showed a tendency towards a
more severe disease course.4 We previously described
a group of adult MS patients who carried a
TNFRSF1A R92Q mutation and showed, in addi-
tion to the typical MS features, symptoms compati-
ble with TRAPS.5,6 Very recently, the TNFRSF1A
gene was identified as a new susceptibility locus
for MS.7
Here, we report a patient with childhood MS and
coexisting mutations in the TNFRSF1A and MEFV
genes.
Case report
Course and diagnosis of MS
At the age of 14, the girl had a first episode of left-sided
paraesthesias and impaired hearing. Three months
later, she presented with double vision, nystagmus,
and impaired balance. A cerebral magnetic resonance
imaging (MRI) scan performed at that time showed
multiple hyperintense lesions involving also the brain-
stem, some of them with gadolinium (Gd)
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enhancement. Cerebrospinal fluid (CSF) analysis
revealed positive oligoclonal bands. The diagnosis of
MS was made according to the McDonald criteria.
During the following year, she had three more relapses
before immunomodulatory treatment with intramuscu-
lar interferon beta (IFNb) was started, initially with a
quarter of the adult dose. When the dose was increased
to half of the adult dose, she experienced several side
effects such as extensive flu-like symptoms, myalgias,
headaches, chest pain, and on one occasion a minimal
pericardial effusion. All these symptoms did not
respond well to anti-inflammatory medication.
Repeated MRI scans revealed new, partially Gd-
enhanced lesions as well as spinal cord lesions
(Figure 1). Immunomodulatory treatment was changed
to glatiramer acetate, which is tolerated better and is
applied as her current medication.
Symptoms of TRAPS and FMF
Our patient had repeated episodes of pharyngitis in
childhood. Attacks of thoracic pain and myalgia
occurred before the diagnosis of MS and initiation of
immunomodulatory treatment. In addition, she had
experienced frequent headaches since early childhood.
In contrast, no rashes or episodes of fever were
reported. None of these symptoms was brought to med-
ical attention before the diagnosis of MS was made.
Genetic testing revealed heterozygosity for an argi-
nine92 (CGG)! glutamine (CAG)/R92Q substitution
encoded by exon 4 of the TNFRSF1A gene and a glu-
tamic acid230 (GAA)! lysine (AAA)/E230K mutation
encoded by exon 2 of the MEFV gene. Her laboratory
workup revealed a mild increase of serum amyloid
A and a mildly elevated anti-nuclear antibody
(A) (B)
(C)
Figure 1. MRI of our patient A) T2-weighted sequence, axial plane, demonstrating multiple hyperintense lesions periventricular,
cortical, and juxtacortical, B) corresponding T1-weighted sequence with Gd-enhanced lesions, C) T2 spinal sequence with multiple
hyperintense lesions.
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titre of 1 : 60. There was no evidence of an additional
rheumatologic disease or a pathologic renal function.
Family members
The patient inherited the TNFRSF1A R92Q mutation
from her mother, who had a past history of episodic
arthralgia, but no further complaints. Her father was
the carrier of the pyrin E230K substitution. A detailed
medical history revealed severe migraine as the only
symptom attributable to FMF. Her sister had a long-
standing severe migraine as well as intermittent abdom-
inal pain with constipation. She also tested positive for
the pyrin E230K exchange. A maternal grandmother
had an unclassified rheumatologic disorder with
arthralgia/arthritis (see Figure 2A).
Discussion
Our patient inherited two point mutations, one in the
TNFRSF1A gene from her mother and the other in the
MEFV gene from her father. Her past medical history
revealed symptoms attributable to TRAPS and FMF,
including headaches and myalgias as well as episodes of
thoracic pain and recurrent pharyngitis in childhood.
Interestingly, she lacked the typical fever episodes.
The TNFRSF1A R92Q mutation is known to be
associated with a more heterogeneous spectrum of
symptoms with or without typical fever flares.8 Nine
patients with a heterozygous pyrin E230K mutation
have been reported in the literature, one described as
a clinically severe phenotype.9 For the remaining eight
patients, no such information is available.
Our patient met the criteria of McDonald and had
the typical CSF changes. Her disease course is highly
active with seven relapses in 2 years. She had to discon-
tinue the first immunomodulatory treatment with IFNb
at half of the adult dosage because of severe side effects,
similar to some adult MS patients carrying the
TNFRSF1A R92Q mutation.6
The severe MS course was aggravated by concomi-
tant symptoms of TRAPS and FMF. For mutations in
the TNFRSF1A and MEFV genes, an augmentation of
the inflammatory response leading to a ‘hyperinflam-
matory state’ has been suggested (Figure 2B). The path-
ogenesis of TRAPS is mediated via TNF-a and
TNFRSF1A signalling pathways. Animal experiments
and clinical studies suggest that dysregulation of these
complex pathways also plays an important role in the
pathogenesis of MS.10 In addition, the TNFRSF1A
R92Q variant has been identified as a new susceptibility
locus for MS in a recent genome-wide association
study.7 In FMF, inflammation is supposed to be related
to a reduced ability of pyrin, the gene product
of MEFV, to control interleukin-1b activation.
An association of FMF with other autoinflammatory
diseases, such as Henoch-Scho¨nlein purpura and poly-
arteritis nodosa, is well established, with earliest reports
dating back to the 1950s.3 An interrelation between
FMF and demyelinating CNS disease, in contrast, is
still debated. In a cohort of turkish FMF cases, the
number of MS patients was about four times higher
than expected from the prevalence of MS in Turkey.3
In a cohort of Jewish MS patients, who carried one
MEFV mutation, a tendency towards a more severe
disease course of MS was noted.4
R92Q E230K













Figure 2. (A) Pedigree of the patient. Filled black symbols:
pyrin E230K mutation encoded by exon 2 of the MEFV gene;
white symbol: TNFRSF1A R92Q substitution; black and white
symbol: pyrin E230K and TNFRSF1A R92Q mutation. (B) TRAPS
is associated with mutations in the TNFRSF1A gene, which are
responsible for increased activity of the proinflammatory cyto-
kine TNF-alpha. FMF is caused by mutations in the MEFV gene
(coding for pyrin), which indirectly cause increased production of
interleukin-1b. Both cytokines, TNF-alpha and interleukin-1b,
could profoundly affect both innate and adaptive immune
responses in multiple sclerosis. In the described patient, the
combination of mutations might induce a ‘hyperinflammatory
state’, predisposing to MS.
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In conclusion, this is the first description of a patient
with severe childhood MS and alterations in two auto-
inflammatory disease genes. The mutations were asso-
ciated with additional symptoms such as myalgias,
headache and thoracic pain, which could not be attrib-
uted to MS and complicated MS treatment. They also
may have led to an earlier MS manifestation and could
augment the inflammatory response, thereby leading to
a very active disease course as observed in our patient.
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